Research Article| Volume 20, ISSUE 1, P17-20, February 1999

Hypercoagulability state in hip and knee surgery: influence of ABO antigenic system and allogenic transfusion


      It is well know that people with blood group O have a lower risk for venous thromboembolic disease (VTED) than does the general population. Moreover blood transfusion has been identified as a risk factor for VTED in patients with major trauma. The aim of this work is to investigate the behaviour of several markers of hypercoagulability before and after substitutive surgery of hip and knee in order to evaluate the relationship between the plasmatic levels of these markers, the ABO antigenic system and the allogenic blood transfusion.
      The plasmatic levels of D dimer (D–D), thrombin – antithrombin complex (TAT), and fragment 1 + 2 of prothrombin (F1 + 2) have been determined by the ELISA method in 79 patients subject to substitutive surgery of hip or knee one day before and one day after surgery.
      The 41 patients with blood groups different from O had presurgical levels of F1 + 2 higher than those of group O (p=0.004), while no differences could be found for D–D and TAT. The 28 patients who received allogenic blood presented higher levels of D–D one day after surgery than non-transfused patients (p=0.043); the practice of transfusion did not modify significantly the levels of TAT and F1 + 2 after surgery.
      In accordance with these results we suggest that blood group and transfusion are risk factors for hypercoagulability, and therefore we advise for a restrictive policy of transfusion practice. New therapies such as aprotinin should be assayed in order to minimize blood loss.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Jack H, Sloe D, Westerholm B, Inman WHW, Vessey MP, Shapiro S, Lewis G, Worcester J. Venous Thromboembolic disease and ABO blood type. Lancet 1969;i:539–542

      2. Talbot S, Ryrie D, Walkley EJ, Langman MJS. ABO blood groups and venous thromboembolic disease. Lancet. 1970;i:1257–1259

      3. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep vein thrombosis within a defined urban population. J. Intern. Med. 1992;232:155–160

      4. Salvati EA, Lachiewicz P. Thromboembolism following total hip-replacement arthroplasty. The efficacy of dextran-warfarin in prophylaxis. J. Bone Joint Surg. 1976;58-A:921–925

      5. Koster T, Blann AD, Briët E, Vandenbroucke J, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152–155

      6. Gill JC, Endress-Brooks J, Bauer PJ, Marks WJ Jr., Montgomery RR. The effect of ABO blood groups on the diagnosis of von Willebrand disease. Blood. 1987;69:1691–1695

      7. Caekebeke-Peerlinck KMJ, Koster T, Briët E. Bleeding time, blood groups and von Willebrand factor. Br. J. Haematol. 1989;73:217–220

      8. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N. Engl. J. Med. 1994;331:1601–1606

      9. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N. Engl. J.Med. 1996;335:701–707

      10. European Consensus Statement. Prevention of venous thromboembolism. Int. Angiol. 1992;11:151–159

      11. Sikorski JM, Hampson WG, Staddon GE. The natural history and aetiology of deep vein thrombosis after hip replacement. J Bone Joint Surg. 1981;63-B:171–177

      12. Nowak-Gottl U, Schaudin E, Hoffmann C, Eckhoff-Donovan S, Merthes N. Intraoperative clotting factor dilution and activated hemostasis in children with Ewinǵs sarcoma or osteosarcoma: a prospective longitudinal study. Haematologica. 1995;80(4):311–317

      13. Menges T, Rupp D, van Lessen A, Hempelmann G. Measures for reducing the use of homologous blood. Effects on blood coagulation during total endoprothesis. Anaesthesist. 1992;41(19):27–33

      14. Utada K, Matayoshi I, Sumi C, Itaya M, Miyawasaki H, Ito M, Tamura H, Mitsukuji I. Aprotinin 2 million KIU reduces perioperative blood loss in patients undergoing primary total hip replacement. Masui. 1997;46(1):77–82

      15. Murkin JM, Shannon NA, Bourne RB, Rorabeck CH, Cruickshank M, Wyile G. Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth. Analg. 1995;80(2):343–348